[1] Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins[J]. J Clin Pharm Ther, 2010, 35(2): 139-151.
[2] 傅志君, 尤启冬, 唐伟方, 等. 他汀类药物作用模式和构效关系研究进展[J]. 中国药学杂志, 2003, 38(6): 404-407.
[3] Tiwari A, Bansal V, Chugh A, et al. Statins and myotoxicity: a therapeutic limitation[J]. Expert Opin Drug Saf, 2006, 5(5): 651-666.
[4] Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors[J]. Clin Pharmacokinet, 2002, 41(5): 343-370.
[5] Morishita R, Tomita N, Ogihara T. HMG-Co A reductase inhibitors in the treatment of cardio- vascular diseases: stabilization of coronary artery plaque[J]. Curr Drug Targets, 2002, 3(5): 379- 385.
[6] Funatsu T, Kakuta H, Takasu T, et al. Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model[J]. Metabolism, 2003, 52(5): 609-615.
[7] 马利平, 孙永红, 郑筱祥. SD大鼠高脂血症的造模方法[J]. 浙江中医学院学报, 1999, 3(2): 16.
[8] Black AE, Hayes RN, Roth BD, et al. Metabolism and excretion of atorvastatin in rats and dogs[J]. Drug Metab Dispos, 1999, 27(8): 916-923.
[9] Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the- counter statins simvastatin, lovastatin, fluvastatin and pravastatin[J]. Clin Pharmacokinet, 2008, 47(7): 463-474.
[10] Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)[J]. Am J Cardiol, 1998, 81(5): 582-587.
[11] 黄晓晖, 谢海棠, 史军, 等. 现代定量药理学的研究进展及展望[J]. 中国临床药理学与治疗学, 2009, 14(6): 601-612.
[12] 黄晓晖, 史军, 李俊,等. 药代动力学和药效动力学中数学建模与模拟的基本原理(1)[J]. 中国临床药理学与治疗学, 2007, 12(1): 82-89.
[13] 董梅, 付强. 高剂量表阿霉素在肿瘤患者中的药物动力学和药效学研究(英文)[J]. J Chin Pharm Sci, 2000, 9(2): 92-95.
[14] 盛玉成, 何迎春, 杨娟, 等. 药代动力学比例化剂量反应关系的研究方法及其线性评价[J]. 中国临床药理学杂志, 2010, 26(5): 376-381. |
